New Zealand - English - Ministry for Primary Industries

bayer new zealand limited - indaziflam - suspension concentrate - indaziflam 500 g/litre - herbicide - herbicide

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - ribociclib succinate, quantity: 254.4 mg (equivalent: ribociclib, qty 200 mg) - tablet, film coated - excipient ingredients: colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; hyprolose; crospovidone; titanium dioxide; purified talc; xanthan gum; polyvinyl alcohol; lecithin; iron oxide black; iron oxide red - kisqali is indicated for the treatment of patients with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor or fulvestrant, as initial endocrine-based therapy or following prior endocrine therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - galcanezumab, quantity: 120 mg/ml - injection, solution - excipient ingredients: histidine hydrochloride monohydrate; water for injections; histidine; sodium chloride; polysorbate 80 - emgality is indicated for the prophylaxis of migraine in adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - galcanezumab, quantity: 120 mg/ml - injection, solution - excipient ingredients: histidine; water for injections; polysorbate 80; sodium chloride; histidine hydrochloride monohydrate - emgality is indicated for the prophylaxis of migraine in adults.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

delaval pty ltd - alkaline salts - powder - alkaline salts cleanser/sanitiser active 980.0 g/kg - dairy cleanser - milking equipment | milking machine - residue, dirt in milking equipment

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dasco proprietary limited - alkaline salts - soluble powder - alkaline salts cleanser/sanitiser active 960.0 g/kg - dairy cleanser - dairy equipment stainless steel | dairy plant stainless steel | milking equipment | building | milking machine - bacterial prevention, cleansing or disin | disinfecting

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 18.15 mg - capsule - excipient ingredients: microcrystalline cellulose; indigo blue; titanium dioxide; croscarmellose sodium; gelatin; purified talc; colloidal anhydrous silica; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),lenalidomide-teva is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide-teva is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 12.1 mg - capsule - excipient ingredients: colloidal anhydrous silica; gelatin; croscarmellose sodium; iron oxide yellow; purified talc; microcrystalline cellulose; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),lenalidomide-teva is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide-teva is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 6.05 mg - capsule - excipient ingredients: colloidal anhydrous silica; gelatin; purified talc; microcrystalline cellulose; croscarmellose sodium; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),lenalidomide-teva is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide-teva is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.

Australia - English - Department of Health (Therapeutic Goods Administration)

teva pharma australia pty ltd - lenalidomide hydrochloride monohydrate, quantity: 30.25 mg - capsule - excipient ingredients: gelatin; microcrystalline cellulose; colloidal anhydrous silica; titanium dioxide; purified talc; croscarmellose sodium; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - multiple myeloma (mm),lenalidomide-teva is indicated for the treatment of multiple myeloma.,myelodysplastic syndromes (mds),lenalidomide-teva is indicated for treatment of patients with transfusion-dependent anaemia due to low- or intermediate-1 risk myelodysplastic syndromes associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities.